deferiprone Ferriprox
Selected indexed studies
- Deferiprone (Ferriprox) for iron overload. (Med Lett Drugs Ther, 2012) [PMID:22354281]
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. (JAMA Neurol, 2025) [PMID:39495531]
- Deferiprone: New insight. (Ann N Y Acad Sci, 2005) [PMID:16339662]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Deferiprone in Alzheimer Disease: A Randomized Clinical Trial. (2025) pubmed
- Deferiprone: New insight. (2005) pubmed
- Deferiprone protects against photoreceptor degeneration by inhibiting parthanatos. (2025) pubmed
- Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta-analysis. (2024) pubmed
- Combination chelation therapy. (2023) pubmed
- Deferiprone (Ferriprox) for iron overload. (2012) pubmed
- Iron Chelation Therapy. (2025) pubmed
- Deferiprone. (2010) pubmed
- Deferiprone-associated myelotoxicity. (1994) pubmed
- Pathologically high intraocular pressure disturbs normal iron homeostasis and leads to retinal ganglion cell ferroptosis in glaucoma. (2023) pubmed